Gordon J Freeman
Overview
Explore the profile of Gordon J Freeman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
331
Citations
56643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kong Y, Yue M, Xu C, Zhang J, Hong H, Lu J, et al.
Proc Natl Acad Sci U S A
. 2025 Mar;
122(11):e2418739122.
PMID: 40080642
The importance of macrophages in kidney diseases has been well established; however, the mechanisms underlying the infiltration of macrophages into injured kidneys are not well understood. RGMb is a member...
2.
Saini S, Gadet J, Freeman G, Chiocca E, Mineo M
J Neurooncol
. 2025 Mar;
PMID: 40035950
Purpose: The potent antitumor effects of interleukin 12 (IL12) gene therapy in glioblastoma (GBM) are significantly attenuated by the highly immunosuppressive microenvironment and the upregulation of the PD-1/PD-L1 immune checkpoint....
3.
Stratified analysis identifies HIF-2 as a therapeutic target for highly immune-infiltrated melanomas
Huang A, Burke K, Porter R, Meiger L, Fatouros P, Yang J, et al.
bioRxiv
. 2024 Nov;
PMID: 39554029
While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma over the last decade, the identification of broadly applicable robust biomarkers has been challenging, driven in large part by the...
4.
Georgiev P, Han S, Huang A, Nguyen T, Drijvers J, Creasey H, et al.
Cancer Immunol Res
. 2024 Aug;
12(11):1525-1541.
PMID: 39186561
Progressive decline of the adaptive immune system with increasing age coincides with a sharp increase in cancer incidence. In this study, we set out to understand whether deficits in antitumor...
5.
Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd C, et al.
Mol Cancer
. 2024 Mar;
23(1):56.
PMID: 38491381
One of the major hurdles that has hindered the success of chimeric antigen receptor (CAR) T cell therapies against solid tumors is on-target off-tumor (OTOT) toxicity due to sharing of...
6.
Burke K, Chaudhri A, Freeman G, Sharpe A
Immunity
. 2024 Feb;
57(2):223-244.
PMID: 38354702
Immune responses must be tightly regulated to ensure both optimal protective immunity and tolerance. Costimulatory pathways within the B7:CD28 family provide essential signals for optimal T cell activation and clonal...
7.
Wang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A, et al.
iScience
. 2024 Feb;
27(2):108879.
PMID: 38327771
One of the major barriers that have restricted successful use of chimeric antigen receptor (CAR) T cells in the treatment of solid tumors is an unfavorable tumor microenvironment (TME). We...
8.
Iorgulescu J, Ruthen N, Ahn R, Panagioti E, Gokhale P, Neagu M, et al.
Front Immunol
. 2024 Jan;
14:1297932.
PMID: 38213329
Background: The GL261 and CT2A syngeneic tumor lines are frequently used as immunocompetent orthotopic mouse models of human glioblastoma (huGBM) but demonstrate distinct differences in their responses to immunotherapy. Methods:...
9.
Denize T, Jegede O, Matar S, El Ahmar N, West D, Walton E, et al.
Clin Cancer Res
. 2023 Dec;
30(4):803-813.
PMID: 38060202
Purpose: Programmed cell death protein 1 (PD-1) expression on CD8+TIM-3-LAG-3- tumor-infiltrating cells predicts positive response to PD-1 blockade in metastatic clear-cell renal cell carcinoma (mccRCC). Because inhibition of PD-1 signaling...
10.
Shigemura T, Perrot N, Huang Z, Bhatt R, Sheshdeh A, El Ahmar N, et al.
BMC Cancer
. 2023 Oct;
23(1):1039.
PMID: 37891555
Background: The immune checkpoint HERV-H LTR-associating 2 (HHLA2) is expressed in kidney cancer and various other tumor types. Therapeutics targeting HHLA2 or its inhibitory receptor KIR3DL3 are being developed for...